Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

What was studied

This study tested daraxonrasib, a pill that targets active RAS. It acts on both changed and normal RAS. It was an early trial in people with advanced solid tumors. All of these tumors had RAS gene changes. People took doses from 10 to 400 mg once a day. The team chose 300 mg as the dose for a later trial. This report looks at 168 people with pancreatic cancer. Each of them had been treated before.

What they found

Nearly all of the 168 people had side effects linked to the drug. Some had severe ones, grade 3 or higher. Common ones were rash, diarrhea, nausea, mouth sores, vomiting and tiredness. One group had 26 people with RAS G12 changes. They took 300 mg as their second treatment. In some of them, the tumors shrank. These responses lasted a median of 8.2 months. The typical time before the cancer grew was 8.5 months. The typical time alive was 13.1 months. Another group had 38 people with G12, G13 or Q61 changes. Tumors also shrank in some of them. Their typical time alive was 15.6 months.

What it means for patients

The authors link the drug to severe side effects in some people. These were side effects of grade 3 or higher. The authors also report signs that the drug acted against the tumors. These people had pancreatic cancer with RAS changes and past treatment. The team picked a dose to use in a phase 3 trial.

Why it is not certain yet

This was an early trial, and its main aim was safety. Effects on the tumors were a side aim. The groups with tumor results were small, with 26 and 38 people. The abstract does not describe a comparison group. Some time ranges in the results could not be fully measured.

Source

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

We restate facts from the source record in our own words. The original wording belongs to its publisher.